-
1
-
-
0033517302
-
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators
-
Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709–717.
-
(1999)
N Engl J Med
, vol.341
, pp. 709-717
-
-
Pitt, B.1
Zannad, F.2
Remme, W.J.3
Cody, R.4
Castaigne, A.5
Perez, A.6
Palensky, J.7
Wittes, J.8
-
2
-
-
78650399880
-
Eplerenone in patients with systolic heart failure and mild symptoms
-
Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B; EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011;364:11–21.
-
(2011)
N Engl J Med
, vol.364
, pp. 11-21
-
-
Zannad, F.1
McMurray, J.J.2
Krum, H.3
van Veldhuisen, D.J.4
Swedberg, K.5
Shi, H.6
Vincent, J.7
Pocock, S.J.8
Pitt, B.9
-
3
-
-
0034916015
-
The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study
-
Pitt B, Williams G, Remme W, Martinez F, Lopez-Sendon J, Zannad F, Neaton J, Roniker B, Hurley S, Burns D, Bittman R, Kleiman J. The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study. Cardiovasc Drugs Ther 2001;15:79–87.
-
(2001)
Cardiovasc Drugs Ther
, vol.15
, pp. 79-87
-
-
Pitt, B.1
Williams, G.2
Remme, W.3
Martinez, F.4
Lopez-Sendon, J.5
Zannad, F.6
Neaton, J.7
Roniker, B.8
Hurley, S.9
Burns, D.10
Bittman, R.11
Kleiman, J.12
-
4
-
-
70350733579
-
Use of aldosterone antagonists in heart failure
-
Albert NM, Yancy CW, Liang L, Zhao X, Hernandez AF, Peterson ED, Cannon CP, Fonarow GC. Use of aldosterone antagonists in heart failure. JAMA 2009;302:1658–1665.
-
(2009)
JAMA
, vol.302
, pp. 1658-1665
-
-
Albert, N.M.1
Yancy, C.W.2
Liang, L.3
Zhao, X.4
Hernandez, A.F.5
Peterson, E.D.6
Cannon, C.P.7
Fonarow, G.C.8
-
5
-
-
79958115013
-
Potential impact of optimal implementation of evidence-based heart failure therapies on mortality
-
e3
-
Fonarow GC, Yancy CW, Hernandez AF, Peterson ED, Spertus JA, Heidenreich PA. Potential impact of optimal implementation of evidence-based heart failure therapies on mortality. Am Heart J 2011;161:1024–1030.e3.
-
(2011)
Am Heart J
, vol.161
, pp. 1024-1030
-
-
Fonarow, G.C.1
Yancy, C.W.2
Hernandez, A.F.3
Peterson, E.D.4
Spertus, J.A.5
Heidenreich, P.A.6
-
6
-
-
84920024290
-
Time to retrieve the best benefits from renin angiotensin aldosterone system (RAAS) inhibition in heart failure patients with reduced ejection fraction: lessons from randomized controlled trials and registries
-
Rossignol P, Zannad F, Pitt B. Time to retrieve the best benefits from renin angiotensin aldosterone system (RAAS) inhibition in heart failure patients with reduced ejection fraction: lessons from randomized controlled trials and registries. Int J Cardiol 2014;177:731–733.
-
(2014)
Int J Cardiol
, vol.177
, pp. 731-733
-
-
Rossignol, P.1
Zannad, F.2
Pitt, B.3
-
7
-
-
84989842026
-
Potassium lowering agents: Recommendations for physician and patient education, treatment reappraisal, and serial monitoring of potassium in patients with chronic hyperkalemia
-
Pitt B, Rossignol P. Potassium lowering agents: Recommendations for physician and patient education, treatment reappraisal, and serial monitoring of potassium in patients with chronic hyperkalemia. Pharmacol Res 2016;118:2–4.
-
(2016)
Pharmacol Res
, vol.118
, pp. 2-4
-
-
Pitt, B.1
Rossignol, P.2
-
8
-
-
78649437710
-
Heart failure guidelines, performance measures, and the practice of medicine: mind the gap
-
Ghali JK, Massie BM, Mann DL, Rich MW. Heart failure guidelines, performance measures, and the practice of medicine: mind the gap. J Am Coll Cardiol 2010;56:2077–2080.
-
(2010)
J Am Coll Cardiol
, vol.56
, pp. 2077-2080
-
-
Ghali, J.K.1
Massie, B.M.2
Mann, D.L.3
Rich, M.W.4
-
9
-
-
84886023778
-
Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure)
-
Eschalier R, McMurray JJ, Swedberg K, van Veldhuisen DJ, Krum H, Pocock SJ, Shi H, Vincent J, Rossignol P, Zannad F, Pitt B; EMPHASIS-HF Investigators. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure). J Am Coll Cardiol 2013;62:1585–1593.
-
(2013)
J Am Coll Cardiol
, vol.62
, pp. 1585-1593
-
-
Eschalier, R.1
McMurray, J.J.2
Swedberg, K.3
van Veldhuisen, D.J.4
Krum, H.5
Pocock, S.J.6
Shi, H.7
Vincent, J.8
Rossignol, P.9
Zannad, F.10
Pitt, B.11
-
10
-
-
84899500566
-
Incident hyperkalemia may be an independent therapeutic target in low ejection fraction heart failure patients: insights from the HEAAL study
-
Rossignol P, Dobre D, Gregory D, Massaro J, Kiernan M, Konstam MA, Zannad F. Incident hyperkalemia may be an independent therapeutic target in low ejection fraction heart failure patients: insights from the HEAAL study. Int J Cardiol 2014;173:380–387.
-
(2014)
Int J Cardiol
, vol.173
, pp. 380-387
-
-
Rossignol, P.1
Dobre, D.2
Gregory, D.3
Massaro, J.4
Kiernan, M.5
Konstam, M.A.6
Zannad, F.7
-
11
-
-
84868574835
-
Influence of baseline and worsening renal function on efficacy of spironolactone in patients with severe heart failure: insights from RALES (Randomized Aldactone Evaluation Study)
-
Vardeny O, Wu DH, Desai A, Rossignol P, Zannad F, Pitt B, Solomon SD; RALES Investigators. Influence of baseline and worsening renal function on efficacy of spironolactone in patients with severe heart failure: insights from RALES (Randomized Aldactone Evaluation Study). J Am Coll Cardiol 2012;60:2082–2089.
-
(2012)
J Am Coll Cardiol
, vol.60
, pp. 2082-2089
-
-
Vardeny, O.1
Wu, D.H.2
Desai, A.3
Rossignol, P.4
Zannad, F.5
Pitt, B.6
Solomon, S.D.7
-
12
-
-
84907389177
-
Incidence, predictors, and outcomes related to hypo- and hyperkalemia in patients with severe heart failure treated with a mineralocorticoid receptor antagonist
-
Vardeny O, Claggett B, Anand I, Rossignol P, Desai AS, Zannad F, Pitt B, Solomon SD; Randomized Aldactone Evaluation Study (RALES) Investigators. Incidence, predictors, and outcomes related to hypo- and hyperkalemia in patients with severe heart failure treated with a mineralocorticoid receptor antagonist. Circ Heart Fail 2014;7:573–579.
-
(2014)
Circ Heart Fail
, vol.7
, pp. 573-579
-
-
Vardeny, O.1
Claggett, B.2
Anand, I.3
Rossignol, P.4
Desai, A.S.5
Zannad, F.6
Pitt, B.7
Solomon, S.D.8
-
13
-
-
84869417804
-
Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice
-
Zannad F, Gattis Stough W, Rossignol P, Bauersachs J, McMurray JJ, Swedberg K, Struthers AD, Voors AA, Ruilope LM, Bakris GL, O'Connor CM, Gheorghiade M, Mentz RJ, Cohen-Solal A, Maggioni AP, Beygui F, Filippatos GS, Massy ZA, Pathak A, Piña IL, Sabbah HN, Sica DA, Tavazzi L, Pitt B. Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice. Eur Heart J 2012;33:2782–2795.
-
(2012)
Eur Heart J
, vol.33
, pp. 2782-2795
-
-
Zannad, F.1
Gattis Stough, W.2
Rossignol, P.3
Bauersachs, J.4
McMurray, J.J.5
Swedberg, K.6
Struthers, A.D.7
Voors, A.A.8
Ruilope, L.M.9
Bakris, G.L.10
O'Connor, C.M.11
Gheorghiade, M.12
Mentz, R.J.13
Cohen-Solal, A.14
Maggioni, A.P.15
Beygui, F.16
Filippatos, G.S.17
Massy, Z.A.18
Pathak, A.19
Piña, I.L.20
Sabbah, H.N.21
Sica, D.A.22
Tavazzi, L.23
Pitt, B.24
more..
-
14
-
-
85006197330
-
Temporal trends and hospital variation in mineralocorticoid receptor antagonist use in veterans discharged with heart failure
-
Dev S, Lacy ME, Masoudi FA, Wu WC. Temporal trends and hospital variation in mineralocorticoid receptor antagonist use in veterans discharged with heart failure. J Am Heart Assoc 2015;4:e002268.
-
(2015)
J Am Heart Assoc
, vol.4
-
-
Dev, S.1
Lacy, M.E.2
Masoudi, F.A.3
Wu, W.C.4
-
15
-
-
79956213148
-
Use, tolerability and compliance of spironolactone in the treatment of heart failure
-
Lachaine J, Beauchemin C, Ramos E. Use, tolerability and compliance of spironolactone in the treatment of heart failure. BMC Clin Pharmacol 2011;11:4.
-
(2011)
BMC Clin Pharmacol
, vol.11
, pp. 4
-
-
Lachaine, J.1
Beauchemin, C.2
Ramos, E.3
-
16
-
-
77957763788
-
Adherence to aldosterone-blocking agents in patients with heart failure
-
Margolis J, Gerber RA, Roberts C, Gheorghiade M. Adherence to aldosterone-blocking agents in patients with heart failure. Am J Ther 2010;17:446–454.
-
(2010)
Am J Ther
, vol.17
, pp. 446-454
-
-
Margolis, J.1
Gerber, R.A.2
Roberts, C.3
Gheorghiade, M.4
-
17
-
-
84869840351
-
Associations between aldosterone antagonist therapy and risks of mortality and readmission among patients with heart failure and reduced ejection fraction
-
Hernandez AF, Mi X, Hammill BG, Hammill SC, Heidenreich PA, Masoudi FA, Qualls LG, Peterson ED, Fonarow GC, Curtis LH. Associations between aldosterone antagonist therapy and risks of mortality and readmission among patients with heart failure and reduced ejection fraction. JAMA 2012;308;2097–2107.
-
(2012)
JAMA
, vol.308
, pp. 2097-2107
-
-
Hernandez, A.F.1
Mi, X.2
Hammill, B.G.3
Hammill, S.C.4
Heidenreich, P.A.5
Masoudi, F.A.6
Qualls, L.G.7
Peterson, E.D.8
Fonarow, G.C.9
Curtis, L.H.10
-
18
-
-
85005965459
-
Lack of evidence of lower 30-day all-cause readmission in Medicare beneficiaries with heart failure and reduced ejection fraction discharged on spironolactone
-
Lam PH, Dooley DJ, Inampudi C, Arundel C, Fonarow GC, Butler J, Wu WC, Blackman MR, Anker MS, Deedwania P, White M, Prabhu SD, Morgan CJ, Love TE, Aronow WS, Allman RM, Ahmed A. Lack of evidence of lower 30-day all-cause readmission in Medicare beneficiaries with heart failure and reduced ejection fraction discharged on spironolactone. Int J Cardiol 2017;227:462–466.
-
(2017)
Int J Cardiol
, vol.227
, pp. 462-466
-
-
Lam, P.H.1
Dooley, D.J.2
Inampudi, C.3
Arundel, C.4
Fonarow, G.C.5
Butler, J.6
Wu, W.C.7
Blackman, M.R.8
Anker, M.S.9
Deedwania, P.10
White, M.11
Prabhu, S.D.12
Morgan, C.J.13
Love, T.E.14
Aronow, W.S.15
Allman, R.M.16
Ahmed, A.17
-
19
-
-
84975247416
-
A systems BIOlogy Study to TAilored Treatment in Chronic Heart Failure: rationale, design, and baseline characteristics of BIOSTAT-CHF
-
Voors AA, Anker SD, Cleland JG, Dickstein K, Filippatos G, van der Harst P, Hillege HL, Lang CC, Ter Maaten JM, Ng L, Ponikowski P, Samani NJ, van Veldhuisen DJ, Zannad F, Zwinderman AH, Metra M. A systems BIOlogy Study to TAilored Treatment in Chronic Heart Failure: rationale, design, and baseline characteristics of BIOSTAT-CHF. Eur J Heart Fail 2016;18:716–726.
-
(2016)
Eur J Heart Fail
, vol.18
, pp. 716-726
-
-
Voors, A.A.1
Anker, S.D.2
Cleland, J.G.3
Dickstein, K.4
Filippatos, G.5
van der Harst, P.6
Hillege, H.L.7
Lang, C.C.8
Ter Maaten, J.M.9
Ng, L.10
Ponikowski, P.11
Samani, N.J.12
van Veldhuisen, D.J.13
Zannad, F.14
Zwinderman, A.H.15
Metra, M.16
-
20
-
-
84864477617
-
ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC
-
McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Køber L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Rønnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012;14:803–869.
-
(2012)
Eur J Heart Fail
, vol.14
, pp. 803-869
-
-
McMurray, J.J.1
Adamopoulos, S.2
Anker, S.D.3
Auricchio, A.4
Böhm, M.5
Dickstein, K.6
Falk, V.7
Filippatos, G.8
Fonseca, C.9
Gomez-Sanchez, M.A.10
Jaarsma, T.11
Køber, L.12
Lip, G.Y.13
Maggioni, A.P.14
Parkhomenko, A.15
Pieske, B.M.16
Popescu, B.A.17
Rønnevik, P.K.18
Rutten, F.H.19
Schwitter, J.20
Seferovic, P.21
Stepinska, J.22
Trindade, P.T.23
Voors, A.A.24
Zannad, F.25
Zeiher, A.26
more..
-
21
-
-
53249090182
-
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM)
-
Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, Strömberg A, van Veldhuisen DJ, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K; ESC Committee for Practice Guidelines (CPG). ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008;29:2388–2442.
-
(2008)
Eur Heart J
, vol.29
, pp. 2388-2442
-
-
Dickstein, K.1
Cohen-Solal, A.2
Filippatos, G.3
McMurray, J.J.4
Ponikowski, P.5
Poole-Wilson, P.A.6
Strömberg, A.7
van Veldhuisen, D.J.8
Atar, D.9
Hoes, A.W.10
Keren, A.11
Mebazaa, A.12
Nieminen, M.13
Priori, S.G.14
Swedberg, K.15
-
22
-
-
65649142017
-
CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate
-
Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150:604–612.
-
(2009)
Ann Intern Med
, vol.150
, pp. 604-612
-
-
Levey, A.S.1
Stevens, L.A.2
Schmid, C.H.3
Zhang, Y.L.4
Castro, A.F.5
Feldman, H.I.6
Kusek, J.W.7
Eggers, P.8
Van Lente, F.9
Greene, T.10
Coresh, J.11
-
23
-
-
85009990579
-
Comparison of propensity score methods and covariate adjustment: evaluation in 4 cardiovascular studies
-
Elze MC, Gregson J, Baber U, Williamson E, Sartori S, Mehran R, Nichols M, Stone GW, Pocock SJ. Comparison of propensity score methods and covariate adjustment: evaluation in 4 cardiovascular studies. J Am Coll Cardiol 2017;69:345–357.
-
(2017)
J Am Coll Cardiol
, vol.69
, pp. 345-357
-
-
Elze, M.C.1
Gregson, J.2
Baber, U.3
Williamson, E.4
Sartori, S.5
Mehran, R.6
Nichols, M.7
Stone, G.W.8
Pocock, S.J.9
-
24
-
-
84947863698
-
Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial
-
Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes G, Ford I, Cruickshank JK, Caulfield MJ, Salsbury J, Mackenzie I, Padmanabhan S, Brown MJ; British Hypertension Society's PATHWAY Studies Group. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet 2015;386:2059–2068.
-
(2015)
Lancet
, vol.386
, pp. 2059-2068
-
-
Williams, B.1
MacDonald, T.M.2
Morant, S.3
Webb, D.J.4
Sever, P.5
McInnes, G.6
Ford, I.7
Cruickshank, J.K.8
Caulfield, M.J.9
Salsbury, J.10
Mackenzie, I.11
Padmanabhan, S.12
Brown, M.J.13
-
25
-
-
84929688304
-
Mineralocorticoid receptor blockade prevents Western diet-induced diastolic dysfunction in female mice
-
Bostick B, Habibi J, DeMarco VG, Jia G, Domeier TL, Lambert MD, Aroor AR, Nistala R, Bender SB, Garro M, Hayden MR, Ma L, Manrique C, Sowers JR. Mineralocorticoid receptor blockade prevents Western diet-induced diastolic dysfunction in female mice. Am J Physiol Heart Circ Physiol 2015;308:H1126–H1135.
-
(2015)
Am J Physiol Heart Circ Physiol
, vol.308
, pp. H1126-H1135
-
-
Bostick, B.1
Habibi, J.2
DeMarco, V.G.3
Jia, G.4
Domeier, T.L.5
Lambert, M.D.6
Aroor, A.R.7
Nistala, R.8
Bender, S.B.9
Garro, M.10
Hayden, M.R.11
Ma, L.12
Manrique, C.13
Sowers, J.R.14
-
26
-
-
85015286169
-
Effect of eplerenone in patients with heart failure and reduced ejection fraction: potential effect modification by abdominal obesity. Insight from EMPHASIS-HF trial
-
191186–1197
-
Olivier A, Pitt B, Girerd N, Lamiral Z, Machu JL, McMurray JJ, Swedberg K, van Veldhuisen DJ, Collier TJ, Pocock SJ, Rossignol P, Zannad F, Pizard A. Effect of eplerenone in patients with heart failure and reduced ejection fraction: potential effect modification by abdominal obesity. Insight from EMPHASIS-HF trial. Eur J Heart Fail 2017;19:1186–1197.
-
(2017)
Eur J Heart Fail
-
-
Olivier, A.1
Pitt, B.2
Girerd, N.3
Lamiral, Z.4
Machu, J.L.5
McMurray, J.J.6
Swedberg, K.7
van Veldhuisen, D.J.8
Collier, T.J.9
Pocock, S.J.10
Rossignol, P.11
Zannad, F.12
Pizard, A.13
-
27
-
-
85017459818
-
Tailoring mineralocorticoid receptor antagonist therapy in heart failure patients: are we moving towards a personalized approach?
-
19974–986
-
Ferreira JP, Mentz RJ, Pizard A, Pitt B, Zannad F. Tailoring mineralocorticoid receptor antagonist therapy in heart failure patients: are we moving towards a personalized approach? Eur J Heart Fail 2017;19:974–986.
-
(2017)
Eur J Heart Fail
-
-
Ferreira, J.P.1
Mentz, R.J.2
Pizard, A.3
Pitt, B.4
Zannad, F.5
-
28
-
-
77957244692
-
EURObservational Research Programme: the Heart Failure Pilot Survey (ESC-HF Pilot)
-
Maggioni AP, Dahlström U, Filippatos G, Chioncel O, Leiro MC, Drozdz J, Fruhwald F, Gullestad L, Logeart D, Metra M, Parissis J, Persson H, Ponikowski P, Rauchhaus M, Voors A, Nielsen OW, Zannad F, Tavazzi L; Heart Failure Association of ESC (HFA). EURObservational Research Programme: the Heart Failure Pilot Survey (ESC-HF Pilot). Eur J Heart Fail 2010;12:1076–1084.
-
(2010)
Eur J Heart Fail
, vol.12
, pp. 1076-1084
-
-
Maggioni, A.P.1
Dahlström, U.2
Filippatos, G.3
Chioncel, O.4
Leiro, M.C.5
Drozdz, J.6
Fruhwald, F.7
Gullestad, L.8
Logeart, D.9
Metra, M.10
Parissis, J.11
Persson, H.12
Ponikowski, P.13
Rauchhaus, M.14
Voors, A.15
Nielsen, O.W.16
Zannad, F.17
Tavazzi, L.18
-
29
-
-
84880077072
-
Transitional adherence and persistence in the use of aldosterone antagonist therapy in patients with heart failure
-
e1
-
Curtis LH, Mi X, Qualls LG, Check DK, Hammill BG, Hammill SC, Heidenreich PA, Masoudi FA, Setoguchi S, Hernandez AF, Fonarow GC. Transitional adherence and persistence in the use of aldosterone antagonist therapy in patients with heart failure. Am Heart J 2013;165:979–986.e1.
-
(2013)
Am Heart J
, vol.165
, pp. 979-986
-
-
Curtis, L.H.1
Mi, X.2
Qualls, L.G.3
Check, D.K.4
Hammill, B.G.5
Hammill, S.C.6
Heidenreich, P.A.7
Masoudi, F.A.8
Setoguchi, S.9
Hernandez, A.F.10
Fonarow, G.C.11
-
30
-
-
21844459736
-
Adoption of spironolactone therapy for older patients with heart failure and left ventricular systolic dysfunction in the United States, 1998–2001
-
Masoudi FA, Gross CP, Wang Y, Rathore SS, Havranek EP, Foody JM, Krumholz HM. Adoption of spironolactone therapy for older patients with heart failure and left ventricular systolic dysfunction in the United States, 1998–2001. Circulation 2005;112:39–47.
-
(2005)
Circulation
, vol.112
, pp. 39-47
-
-
Masoudi, F.A.1
Gross, C.P.2
Wang, Y.3
Rathore, S.S.4
Havranek, E.P.5
Foody, J.M.6
Krumholz, H.M.7
-
31
-
-
84981715657
-
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC
-
2016;
-
Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2016;18:891–975.
-
(2016)
Eur J Heart Fail
, vol.18
, pp. 891-975
-
-
Ponikowski, P.1
Voors, A.A.2
Anker, S.D.3
Bueno, H.4
Cleland, J.G.5
Coats, A.J.6
Falk, V.7
González-Juanatey, J.R.8
Harjola, V.P.9
Jankowska, E.A.10
Jessup, M.11
Linde, C.12
Nihoyannopoulos, P.13
Parissis, J.T.14
Pieske, B.15
Riley, J.P.16
Rosano, G.M.17
Ruilope, L.M.18
Ruschitzka, F.19
Rutten, F.H.20
van der Meer, P.21
more..
-
32
-
-
3442886513
-
Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study
-
Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, Redelmeier DA. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004;351:543–551.
-
(2004)
N Engl J Med
, vol.351
, pp. 543-551
-
-
Juurlink, D.N.1
Mamdani, M.M.2
Lee, D.S.3
Kopp, A.4
Austin, P.C.5
Laupacis, A.6
Redelmeier, D.A.7
-
33
-
-
0037438820
-
Complications of inappropriate use of spironolactone in heart failure: when an old medicine spirals out of new guidelines
-
Bozkurt B, Agoston I, Knowlton AA. Complications of inappropriate use of spironolactone in heart failure: when an old medicine spirals out of new guidelines. J Am Coll Cardiol 2003;41:211–214.
-
(2003)
J Am Coll Cardiol
, vol.41
, pp. 211-214
-
-
Bozkurt, B.1
Agoston, I.2
Knowlton, A.A.3
-
34
-
-
33645824752
-
Use and side-effect profile of spironolactone in a private cardiologist's practice
-
Williams EM, Katholi RE, Karambelas MR. Use and side-effect profile of spironolactone in a private cardiologist's practice. Clin Cardiol 2006;29:149–153.
-
(2006)
Clin Cardiol
, vol.29
, pp. 149-153
-
-
Williams, E.M.1
Katholi, R.E.2
Karambelas, M.R.3
-
35
-
-
24044466543
-
The adequacy of laboratory monitoring in patients treated with spironolactone for congestive heart failure
-
Shah KB, Rao K, Sawyer R, Gottlieb SS. The adequacy of laboratory monitoring in patients treated with spironolactone for congestive heart failure. J Am Coll Cardiol 2005;46:845–849.
-
(2005)
J Am Coll Cardiol
, vol.46
, pp. 845-849
-
-
Shah, K.B.1
Rao, K.2
Sawyer, R.3
Gottlieb, S.S.4
-
36
-
-
84946761083
-
Consistency of laboratory monitoring during initiation of mineralocorticoid receptor antagonist therapy in patients with heart failure
-
Cooper LB, Hammill BG, Peterson ED, Pitt B, Maciejewski ML, Curtis LH, Hernandez AF. Consistency of laboratory monitoring during initiation of mineralocorticoid receptor antagonist therapy in patients with heart failure. JAMA 2015;314:1973–1975.
-
(2015)
JAMA
, vol.314
, pp. 1973-1975
-
-
Cooper, L.B.1
Hammill, B.G.2
Peterson, E.D.3
Pitt, B.4
Maciejewski, M.L.5
Curtis, L.H.6
Hernandez, A.F.7
-
37
-
-
0034727695
-
Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators
-
Zannad F, Alla F, Dousset B, Perez A, Pitt B. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation 2000;102:2700–2706.
-
(2000)
Circulation
, vol.102
, pp. 2700-2706
-
-
Zannad, F.1
Alla, F.2
Dousset, B.3
Perez, A.4
Pitt, B.5
-
38
-
-
34250818053
-
Drug insight: aldosterone-receptor antagonists in heart failure—the journey continues
-
Kalidindi SR, Tang WH, Francis GS. Drug insight: aldosterone-receptor antagonists in heart failure—the journey continues. Nat Clin Pract Cardiovasc Med 2007;4:368–378.
-
(2007)
Nat Clin Pract Cardiovasc Med
, vol.4
, pp. 368-378
-
-
Kalidindi, S.R.1
Tang, W.H.2
Francis, G.S.3
-
39
-
-
84885042198
-
Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC Heart Failure Long-Term Registry
-
Maggioni AP, Anker SD, Dahlström U, Filippatos G, Ponikowski P, Zannad F, Amir O, Chioncel O, Leiro MC, Drozdz J, Erglis A, Fazlibegovic E, Fonseca C, Fruhwald F, Gatzov P, Goncalvesova E, Hassanein M, Hradec J, Kavoliuniene A, Lainscak M, Logeart D, Merkely B, Metra M, Persson H, Seferovic P, Temizhan A, Tousoulis D, Tavazzi L; Heart Failure Association of the ESC. Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail 2013;15:1173–1184.
-
(2013)
Eur J Heart Fail
, vol.15
, pp. 1173-1184
-
-
Maggioni, A.P.1
Anker, S.D.2
Dahlström, U.3
Filippatos, G.4
Ponikowski, P.5
Zannad, F.6
Amir, O.7
Chioncel, O.8
Leiro, M.C.9
Drozdz, J.10
Erglis, A.11
Fazlibegovic, E.12
Fonseca, C.13
Fruhwald, F.14
Gatzov, P.15
Goncalvesova, E.16
Hassanein, M.17
Hradec, J.18
Kavoliuniene, A.19
Lainscak, M.20
Logeart, D.21
Merkely, B.22
Metra, M.23
Persson, H.24
Seferovic, P.25
Temizhan, A.26
Tousoulis, D.27
Tavazzi, L.28
more..
-
40
-
-
84986208142
-
DENERHTN Investigators. Adherence to antihypertensive treatment and the blood pressure-lowering effects of renal denervation in the Renal Denervation for Hypertension (DENERHTN) trial
-
Azizi M, Pereira H, Hamdidouche I, Gosse P, Monge M, Bobrie G, Delsart P, Mounier-Véhier C, Courand PY, Lantelme P, Denolle T, Dourmap-Collas C, Girerd X, Michel Halimi J, Zannad F, Ormezzano O, Vaïsse B, Herpin D, Ribstein J, Chamontin B, Mourad JJ, Ferrari E, Plouin PF, Jullien V, Sapoval M, Chatellier G; DENERHTN Investigators. Adherence to antihypertensive treatment and the blood pressure-lowering effects of renal denervation in the Renal Denervation for Hypertension (DENERHTN) trial. Circulation 2016;134:847–857.
-
(2016)
Circulation
, vol.134
, pp. 847-857
-
-
Azizi, M.1
Pereira, H.2
Hamdidouche, I.3
Gosse, P.4
Monge, M.5
Bobrie, G.6
Delsart, P.7
Mounier-Véhier, C.8
Courand, P.Y.9
Lantelme, P.10
Denolle, T.11
Dourmap-Collas, C.12
Girerd, X.13
Michel Halimi, J.14
Zannad, F.15
Ormezzano, O.16
Vaïsse, B.17
Herpin, D.18
Ribstein, J.19
Chamontin, B.20
Mourad, J.J.21
Ferrari, E.22
Plouin, P.F.23
Jullien, V.24
Sapoval, M.25
Chatellier, G.26
more..
-
41
-
-
53249122867
-
Cardiologists' awareness and perceptions of guidelines for chronic heart failure. The ADDress your Heart survey
-
Erhardt L, Komajda M, Hobbs FD, Soler-Soler J. Cardiologists' awareness and perceptions of guidelines for chronic heart failure. The ADDress your Heart survey. Eur J Heart Fail 2008;10:1020–1025.
-
(2008)
Eur J Heart Fail
, vol.10
, pp. 1020-1025
-
-
Erhardt, L.1
Komajda, M.2
Hobbs, F.D.3
Soler-Soler, J.4
-
42
-
-
85006213941
-
Barriers to adoption of mineralocorticoid receptor antagonists in patients with heart failure: a mixed-methods study
-
Dev S, Hoffman TK, Kavalieratos D, Heidenreich P, Wu WC, Schwenke DC, Tracy SJ. Barriers to adoption of mineralocorticoid receptor antagonists in patients with heart failure: a mixed-methods study. J Am Heart Assoc 2016;5:e002493.
-
(2016)
J Am Heart Assoc
, vol.5
-
-
Dev, S.1
Hoffman, T.K.2
Kavalieratos, D.3
Heidenreich, P.4
Wu, W.C.5
Schwenke, D.C.6
Tracy, S.J.7
-
43
-
-
84896109810
-
Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF)
-
Rossignol P, Dobre D, McMurray JJ, Swedberg K, Krum H, van Veldhuisen DJ, Shi H, Messig M, Vincent J, Girerd N, Bakris G, Pitt B, Zannad F. Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF). Circ Heart Fail 2014;7:51–58.
-
(2014)
Circ Heart Fail
, vol.7
, pp. 51-58
-
-
Rossignol, P.1
Dobre, D.2
McMurray, J.J.3
Swedberg, K.4
Krum, H.5
van Veldhuisen, D.J.6
Shi, H.7
Messig, M.8
Vincent, J.9
Girerd, N.10
Bakris, G.11
Pitt, B.12
Zannad, F.13
-
44
-
-
84879467972
-
EURObservational Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot)
-
Maggioni AP, Dahlström U, Filippatos G, Chioncel O, Crespo Leiro M, Drozdz J, Fruhwald F, Gullestad L, Logeart D, Fabbri G, Urso R, Metra M, Parissis J, Persson H, Ponikowski P, Rauchhaus M, Voors AA, Nielsen OW, Zannad F, Tavazzi L; Heart Failure Association of the European Society of Cardiology (HFA). EURObservational Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot). Eur J Heart Fail 2013;15:808–817.
-
(2013)
Eur J Heart Fail
, vol.15
, pp. 808-817
-
-
Maggioni, A.P.1
Dahlström, U.2
Filippatos, G.3
Chioncel, O.4
Crespo Leiro, M.5
Drozdz, J.6
Fruhwald, F.7
Gullestad, L.8
Logeart, D.9
Fabbri, G.10
Urso, R.11
Metra, M.12
Parissis, J.13
Persson, H.14
Ponikowski, P.15
Rauchhaus, M.16
Voors, A.A.17
Nielsen, O.W.18
Zannad, F.19
Tavazzi, L.20
more..
-
45
-
-
84856260028
-
Medication dosing in outpatients with heart failure after implementation of a practice-based performance improvement intervention: findings from IMPROVE HF
-
Gheorghiade M, Albert NM, Curtis AB, Thomas Heywood J, McBride ML, Inge PJ, Mehra MR, O'Connor CM, Reynolds D, Walsh MN, Yancy CW, Fonarow GC. Medication dosing in outpatients with heart failure after implementation of a practice-based performance improvement intervention: findings from IMPROVE HF. Congest Heart Fail 2012;18:9–17.
-
(2012)
Congest Heart Fail
, vol.18
, pp. 9-17
-
-
Gheorghiade, M.1
Albert, N.M.2
Curtis, A.B.3
Thomas Heywood, J.4
McBride, M.L.5
Inge, P.J.6
Mehra, M.R.7
O'Connor, C.M.8
Reynolds, D.9
Walsh, M.N.10
Yancy, C.W.11
Fonarow, G.C.12
-
46
-
-
85011968147
-
Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors
-
Epstein M, Reaven NL, Funk SE, McGaughey KJ, Oestreicher N, Knispel J. Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors. Am J Manag Care 2015;21(11 Suppl):S212–220.
-
(2015)
Am J Manag Care
, vol.21
, Issue.11
, pp. S212-220
-
-
Epstein, M.1
Reaven, N.L.2
Funk, S.E.3
McGaughey, K.J.4
Oestreicher, N.5
Knispel, J.6
-
47
-
-
33846550667
-
Laboratory monitoring of potassium and creatinine in ambulatory patients receiving angiotensin converting enzyme inhibitors and angiotensin receptor blockers
-
Raebel MA, McClure DL, Simon SR, Chan KA, Feldstein A, Andrade SE, Lafata JE, Roblin D, Davis RL, Gunter MJ, Platt R. Laboratory monitoring of potassium and creatinine in ambulatory patients receiving angiotensin converting enzyme inhibitors and angiotensin receptor blockers. Pharmacoepidemiol Drug Saf 2007;16:55–64.
-
(2007)
Pharmacoepidemiol Drug Saf
, vol.16
, pp. 55-64
-
-
Raebel, M.A.1
McClure, D.L.2
Simon, S.R.3
Chan, K.A.4
Feldstein, A.5
Andrade, S.E.6
Lafata, J.E.7
Roblin, D.8
Davis, R.L.9
Gunter, M.J.10
Platt, R.11
-
48
-
-
84886283448
-
Effectiveness of a multidimensional home nurse led heart failure disease management program—a French nationwide time-series comparison
-
Agrinier N, Altieri C, Alla F, Jay N, Dobre D, Thilly N, Zannad F. Effectiveness of a multidimensional home nurse led heart failure disease management program—a French nationwide time-series comparison. Int J Cardiol 2013;168:3652–3658.
-
(2013)
Int J Cardiol
, vol.168
, pp. 3652-3658
-
-
Agrinier, N.1
Altieri, C.2
Alla, F.3
Jay, N.4
Dobre, D.5
Thilly, N.6
Zannad, F.7
-
49
-
-
82555192608
-
A trial-based economic evaluation of 2 nurse-led disease management programs in heart failure
-
Postmus D, Pari AA, Jaarsma T, Luttik ML, van Veldhuisen DJ, Hillege HL, Buskens E. A trial-based economic evaluation of 2 nurse-led disease management programs in heart failure. Am Heart J 2011;162:1096–1104.
-
(2011)
Am Heart J
, vol.162
, pp. 1096-1104
-
-
Postmus, D.1
Pari, A.A.2
Jaarsma, T.3
Luttik, M.L.4
van Veldhuisen, D.J.5
Hillege, H.L.6
Buskens, E.7
-
50
-
-
84873036063
-
Clinical service organisation for heart failure
-
Takeda A, Taylor SJ, Taylor RS, Khan F, Krum H, Underwood M. Clinical service organisation for heart failure. Cochrane Database Syst Rev 2012;9:CD002752.
-
(2012)
Cochrane Database Syst Rev
, vol.9
, pp. CD002752
-
-
Takeda, A.1
Taylor, S.J.2
Taylor, R.S.3
Khan, F.4
Krum, H.5
Underwood, M.6
|